|
13 Companies |
|
9 Products |
|
9 Products |
|
8 Mechanisms of Action |
|
0 Trials |
|
18 News |
|
- |||| Sylvant (siltuximab) / Jazz
Trial completion: A Study to Evaluate the Safety of Long-term Treatment With Siltuximab in Patients With Multicentric Castleman's Disease (clinicaltrials.gov) - Mar 30, 2018
P2, N=60, Completed, Sponsor: Janssen Research & Development, LLC
Active, not recruiting --> Completed
- |||| Sylvant (siltuximab) / Jazz
Trial completion: A Study to Evaluate the Efficacy and Safety of CNTO328 Plus Best Supportive Care in Multicentric Castleman's Disease (clinicaltrials.gov) - Sep 28, 2017
P2, N=79, Completed, Sponsor: Janssen Research & Development, LLC
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Viracept (nelfinavir) / ViiV Healthcare, Roche
Enrollment change, Trial termination: Nelfinavir for the Treatment of Gammaherpesvirus-Related Tumors (clinicaltrials.gov) - Jun 11, 2016
P0, N=1, Terminated, Sponsor: Sidney Kimmel Comprehensive Cancer Center
N=10 --> 1 | Recruiting --> Terminated; Very slow accrual; terminated to allow resources to be utilized more effectively on other studies. No data analysis completed, nor any conclusions reached.
- Imbruvica (ibrutinib) / AbbVie, J&J
Trial termination, Trial primary completion date: Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With HIV Infection (clinicaltrials.gov) - Aug 13, 2015
P1, N=72, Terminated, Sponsor: National Cancer Institute (NCI)
No data analysis completed, nor any conclusions reached. Recruiting --> Terminated | Trial primary completion date: Aug 2017 --> Jul 2015; Inadequate accrual rate
- || Sylvant (siltuximab) / Jazz
Trial primary completion date: A Study to Evaluate the Safety of Long-term Treatment With Siltuximab in Patients With Multicentric Castleman's Disease (clinicaltrials.gov) - Jun 11, 2015
P2, N=60, Active, not recruiting, Sponsor: Janssen Research & Development, LLC
Recruiting --> Terminated | Trial primary completion date: Aug 2017 --> Jul 2015; Inadequate accrual rate Trial primary completion date: Mar 2015 --> Mar 2017
- Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Clinical: Study of Pomalidomide Combined With Modified DA-EPOCH and Rituximab in KSHV-Associated Lymphomas (clinicaltrials.gov) - May 7, 2015
P1/2, N=0, Withdrawn, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Mar 2015 --> Mar 2017 N=46 --> 0 | Recruiting --> Withdrawn | Trial primary completion date: Jun 2018 --> May 2015
- Viracept (nelfinavir) / ViiV Healthcare, Roche
Enrollment open: Nelfinavir for the Treatment of Gammaherpesvirus-Related Tumors (clinicaltrials.gov) - Nov 18, 2014
P0, N=10, Recruiting, Sponsor: Sidney Kimmel Comprehensive Cancer Center
N=46 --> 0 | Recruiting --> Withdrawn | Trial primary completion date: Jun 2018 --> May 2015 Not yet recruiting --> Recruiting
- Imbruvica (ibrutinib) / AbbVie, J&J
Enrollment open: Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With HIV Infection (clinicaltrials.gov) - Sep 28, 2014
P1, N=72, Recruiting, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Clinical: Study of Pomalidomide Combined With Modified DA-EPOCH and Rituximab in KSHV-Associated Lymphomas (clinicaltrials.gov) - Aug 29, 2014
P1/2, N=46, Recruiting, Sponsor: National Cancer Institute (NCI)
- Imbruvica (ibrutinib) / AbbVie, J&J
Trial initiation date: Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With HIV Infection (clinicaltrials.gov) - Aug 27, 2014
P1, N=72, Not yet recruiting, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting Initiation date: May 2014 --> Aug 2014
- Imbruvica (ibrutinib) / AbbVie, J&J
New P1 trial: Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With HIV Infection (clinicaltrials.gov) - Apr 7, 2014
P1, N=78, Not yet recruiting, Sponsor: National Cancer Institute (NCI)
- ||| Sylvant (siltuximab) / Jazz
Enrollment change: A Study to Evaluate the Safety of Long-term Treatment With Siltuximab in Patients With Multicentric Castleman's Disease (clinicaltrials.gov) - Mar 5, 2014
P2, N=60, Active, not recruiting, Sponsor: Janssen Research & Development, LLC
Initiation date: May 2014 --> Aug 2014 N=75 --> 60
- ||| Sylvant (siltuximab) / Jazz
Enrollment closed: A Study to Evaluate the Safety of Long-term Treatment With Siltuximab in Patients With Multicentric Castleman's Disease (clinicaltrials.gov) - Mar 5, 2014
P2, N=60, Active, not recruiting, Sponsor: Janssen Research & Development, LLC
N=75 --> 60 Enrolling by invitation --> Active, not recruiting
- ||| Sylvant (siltuximab) / Jazz
Enrollment closed: A Study to Evaluate the Efficacy and Safety of CNTO328 Plus Best Supportive Care in Multicentric Castleman's Disease (clinicaltrials.gov) - Jul 31, 2012
P2, N=80, Active, not recruiting, Sponsor: Janssen Research & Development, LLC
Enrolling by invitation --> Active, not recruiting Recruiting --> Active, not recruiting
- Actemra IV (tocilizumab) / Roche, JW Pharma
Trial completion: A Study to Provide RoActemra/Actemra (Tocilzumab) to Patients With Multicentric Castleman's Disease Who Demonstrated Benefit From Previous RoActemra/Actemra Treatment (clinicaltrials.gov) - Dec 4, 2011
P1, N=3, Completed, Sponsor: Hoffmann-La Roche
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- ||| Sylvant (siltuximab) / Jazz
Trial completion: A Safety and Efficacy Study of CNTO 328 in Patients With B-Cell Non-Hodgkin's Lymphoma, Multiple Myeloma, or Castleman's Disease (clinicaltrials.gov) - Nov 30, 2011
P1, N=67, Completed, Sponsor: Centocor, Inc.
Active, not recruiting --> Completed Active, not recruiting --> Completed